Drug eluting medical device
The present disclosure relates to medical devices, and methods for producing and using the devices. In embodiments, the medical device may be a buttress including a porous substrate possessing a therapeutic layer of a chemotherapeutic agent and optional excipient(s) thereon. By varying the form of chemotherapeutic agents and excipients, the medical devices may be used to treat both the area to which the medical device is attached as well as tissue at a distance therefrom.
1. A medical device comprising:
a porous substrate; and
a therapeutic layer having a thickness from about 11 nm to about 218 nm on at least a portion of the porous substrate, the therapeutic layer including a chemotherapeutic agent,
wherein the therapeutic layer has a surface to volume ratio from about 500 mm −1 to about 90,000 mm −1 .
2. The medical device of claim 1 , wherein the chemotherapeutic agent is selected from paclitaxel and derivatives thereof, docetaxel and derivatives thereof, abraxane, tamoxifen, cyclophosphamide, actinomycin, bleomycin, dactinomycin, daunorubicin, doxorubicin, doxorubicin hydrochloride, epirubicin, mitomycin, methotrexate, fluorouracil, gemcitabine, gemcitabine hydrochloride, carboplatin, carmustine, methyl-CCNU, cisplatin, etoposide, camptothecin and derivatives thereof, phenesterine, vinblastine, vincristine, goserelin, leuprolide, interferon alfa, retinoic acid, nitrogen mustard alkylating agents, piposulfan, vinorelbine, irinotecan, irinotecan hydrochloride, vinblastine, pemetrexed, sorafenib tosylate, everolimus, erlotinib hydrochloride, sunitinib malate, capecitabine oxaliplatin, leucovorin calcium, bevacizumab, cetuximab, ramucirumab, trastuzumab, or combinations thereof.
3. The medical device of claim 1 , wherein the chemotherapeutic agent includes a polymorph of paclitaxel.
4. The medical device of claim 3 , wherein the polymorph of paclitaxel is selected from amorphous paclitaxel, crystalline paclitaxel dihydrate, anhydrous paclitaxel, or combinations thereof.
5. The medical device of claim 1 , wherein the porous substrate has a pore volume from about 65% to about 85%.
6. The medical device of claim 1 , wherein the therapeutic layer has a thickness from about from about 25 nm to about 75 nm.
7. The medical device of claim 1 , wherein the therapeutic layer further comprises an excipient selected from 2-hydroxypropyl-beta-cyclodextrin, methyl-ß-cyclodextrin, sodium dodecyl sulfate, octylglucoside, sorbitan monooleate, sorbitan monolaurate, polyethoxylated fatty acid esters of sorbitan, oleic acid, citric acid, ascorbic acid, butylated hydroxytoluene, D-sorbitol, or combinations thereof.
8. The medical device of claim 1 , wherein the medical device is selected from surgical buttresses, hernia patches, staples, tacks, stents, or tissue scaffolds.
9. A method for treating tissue comprising applying the medical device of claim 1 to tissue.
10. The method of claim 9 , wherein applying the medical device to tissue occurs with a fixation device selected from staples, tacks, clips, sutures, adhesives, or combinations thereof.
11. A medical device comprising:
a porous substrate; and
a therapeutic layer having a thickness from about 25 nm to about 75 nm on at least a portion of the porous substrate, the therapeutic layer including a chemotherapeutic agent,
wherein the therapeutic layer has a surface to volume ratio from about 500 mm −1 to about 90,000 mm −1 .
12. The medical device of claim 11 , wherein the chemotherapeutic agent is selected from paclitaxel and derivatives thereof, docetaxel and derivatives thereof, abraxane, tamoxifen, cyclophosphamide, actinomycin, bleomycin, dactinomycin, daunorubicin, doxorubicin, doxorubicin hydrochloride, epirubicin, mitomycin, methotrexate, fluorouracil, gemcitabine, gemcitabine hydrochloride, carboplatin, carmustine, methyl-CCNU, cisplatin, etoposide, camptothecin and derivatives thereof, phenesterine, vinblastine, vincristine, goserelin, leuprolide, interferon alfa, retinoic acid, nitrogen mustard alkylating agents, piposulfan, vinorelbine, irinotecan, irinotecan hydrochloride, vinblastine, pemetrexed, sorafenib tosylate, everolimus, erlotinib hydrochloride, sunitinib malate, capecitabine oxaliplatin, leucovorin calcium, bevacizumab, cetuximab, ramucirumab, trastuzumab, or combinations thereof.
13. The medical device of claim 11 , wherein the chemotherapeutic agent includes a polymorph of paclitaxel.
14. The medical device of claim 13 , wherein the polymorph of paclitaxel is selected from amorphous paclitaxel, crystalline paclitaxel dihydrate, anhydrous paclitaxel, or combinations thereof.
15. The medical device of claim 11 , wherein the medical device has a pore volume from about 65% to about 85%.
16. The medical device of claim 11 , wherein the therapeutic layer further comprises an excipient selected from 2-hydroxypropyl-beta-cyclodextrin, methyl-ß-cyclodextrin, sodium dodecyl sulfate, octylglucoside, sorbitan monooleate, sorbitan monolaurate, polyethoxylated fatty acid esters of sorbitan, oleic acid, citric acid, ascorbic acid, butylated hydroxytoluene, D-sorbitol, or combinations thereof.
17. A method for treating tissue comprising applying the medical device of claim 11 to tissue.
18. The method of claim 17 , wherein applying the medical device to tissue occurs with a fixation device selected from staples, tacks, clips, adhesives, sutures, or combinations thereof.
19. A method of treating cancer, comprising:
introducing to a patient a surgical stapler having a buttress thereon, the buttress including a therapeutic layer on at least a portion of the buttress, the therapeutic layer having a thickness from about 11 nm to about 218 nm and a surface to volume ratio from about 500 mm −1 to about 90,000 mm −1 ; and
using the stapler to remove an undesired portion of an organ and emplace the buttress in a remaining portion of the organ, including stapling the buttress to tissue and cutting the tissue.
20. The method according to claim 19 , wherein the stapler is used on the lung, and the therapeutic layer includes a chemotherapeutic agent.